Open AccessNewly developed type 1 diabetes after coronavirus disease 2019 vaccination: A case report
Author(s) -
Sasaki Hironobu,
Itoh Arata,
Watanabe Yasuhiro,
Nakajima Yuya,
Saisho Yoshifumi,
Irie Junichiro,
Meguro Shu,
Itoh Hiroshi
Publication year - 2022
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.13757
Subject(s) - medicine , vaccination , diabetes mellitus , type 1 diabetes , glycemic , exacerbation , immunology , disease , coronavirus , type 2 diabetes , insulin , covid-19 , endocrinology , infectious disease (medical specialty)
The vaccine for the coronavirus disease 2019 (COVID‐19) has been reported to potentially cause or worsen diabetes. A 73‐year‐old Japanese woman received two doses of Moderna COVID‐19 vaccine. Four weeks after the second vaccination, her glycemic control began to deteriorate, and 8 weeks after the second vaccination, the patient was diagnosed with new‐onset type 1 diabetes that was strongly positive for autoantibodies and showed a disease‐susceptible human leukocyte antigen haplotype, DRB1*04:05:01‐DQB1*04:01:01 . The glucagon stimulation test suggested an insulin‐dependent state, and induction of intensive insulin therapy brought about fair glycemic control. The time period from the COVID‐19 vaccination to the development of type 1 diabetes was relatively longer than to the onset or exacerbation of type 2 diabetes, as previously reported, suggesting the complicated immunological mechanisms for the destruction of β‐cells associated with the vaccination. In recipients with the disease‐susceptible haplotypes, one should be cautious about autoimmune responses for several months after the vaccination.